GSK plc

GSK plc R&D per Employee

The R&D Spending per Employee of GSK plc (GSK.L) as of Nov 1, 2026 is 79,816.30 GBP. In the previous year, R&D Spending per Employee was 58,437.69 GBP — a change of 36.58% (higher).

R&D per Employee

79,816.30GBP

YoY

36.58%

Last updated:

R&D Spending per Employee of GSK plc is 2025 79,816.30 GBP. R&D Spending per Employee of GSK plc was 2024 58,437.69 GBP. It decreases by 36.58% higher compared to the previous year.

The GSK plc R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
38,887.59 GBP
Jan 1, 2019
45,127.89 GBP
Jan 1, 2020
47,615.50 GBP
Jan 1, 2021
46,626.84 GBP
Jan 1, 2022
51,410.71 GBP
Jan 1, 2023
55,758.72 GBP
Jan 1, 2024
58,437.69 GBP
Jan 1, 2025
79,816.30 GBP
The GSK plc R&D per Employee history
YEARR&D per EmployeeYoY
79,816.30GBP+36.58%
58,437.69GBP+4.80%
55,758.72GBP+8.46%
51,410.71GBP+10.26%
46,626.84GBP-2.08%
47,615.50GBP+5.51%
45,127.89GBP+16.05%
38,887.59GBP-5.36%
41,088.17GBP+11.03%
37,005.93GBP+1.78%
36,357.45GBP+2.55%
35,453.83GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

R&D Spending per Employee of GSK plc is 79,816.30 GBP in 2025.

R&D Spending per Employee of GSK plc changed from 58,437.69 GBP to 79,816.30 GBP, representing a 36.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee GSK plc since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's GSK plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — GSK plc

All Key Metrics — GSK plc